Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 4Gynecologic 3Thoracic 2Breast 2

Conditions

Ovarian Neoplasms 3Endometrial Neoplasms 2Neoplasms 1Breast Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Paclitaxel 74pembrolizumab 59Carboplatin 55Bevacizumab 54Specimen Handling 47Magnetic Resonance Spectroscopy 38Cisplatin 32olaparib 28Gemcitabine 25liposomal doxorubicin 24Biopsy 20Taxes 18Topotecan 17Nivolumab 17Doxorubicin 15Cyclophosphamide 15Immunoglobulin G 14Disulfides 14niraparib 12fludarabine 12lenvatinib 11Surveys and Questionnaires 11Letrozole 11atezolizumab 10Drug Therapy 10durvalumab 9Fulvestrant 9Docetaxel 9Brachytherapy 9mirvetuximab soravtansine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
AZD5305 × Gynecologic × 90 days × Clear all
NCT05797168 2026-06-03

FONTANA

AstraZeneca

Phase 1/2 Recruiting
506 enrolled
GynecologicThoracic

Adenocarcinoma of Lung, Ovarian Neoplasms, Endometrial Neoplasms

NCT05123482 2026-05-18

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

AstraZeneca

Phase 1/2 Recruiting
460 enrolled
BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT02264678 2026-05-12

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

AstraZeneca

Phase 1 Active not recruiting
354 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡